Free Access
Med Sci (Paris)
Volume 31, Number 5, Mai 2015
Page(s) 465 - 468
Section Nouvelles
Published online 09 June 2015
  1. Roskoski Jr R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014 ; 79 : 34–74. [CrossRef] [PubMed] [Google Scholar]
  2. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012 ; 12 : 553–563. [CrossRef] [PubMed] [Google Scholar]
  3. Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008 ; 68 : 5878–5887. [CrossRef] [PubMed] [Google Scholar]
  4. Jaiswal BS, Kljavin NM, Stawiski EW, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 2013 ; 23 : 603–617. [CrossRef] [PubMed] [Google Scholar]
  5. Sheng Q, Liu X, Fleming E, et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 2010 ; 17 : 298–310. [CrossRef] [PubMed] [Google Scholar]
  6. Wilson TR, Lee DY, Berry L, et al. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 2011 ; 20 : 158–172. [CrossRef] [PubMed] [Google Scholar]
  7. Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011 ; 3 : 99ra86. [CrossRef] [Google Scholar]
  8. Liles JS, Arnoletti JP, Kossenkov AV, et al. Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma. Br J Cancer 2011 ; 105 : 523–533. [CrossRef] [PubMed] [Google Scholar]
  9. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014 ; 25 : 282–302. [CrossRef] [PubMed] [Google Scholar]
  10. Mujoo K, Choi BK, Huang Z, et al. Regulation of ERBB3/HER3 signaling in cancer. Oncotarget 2014 ; 5 : 10222–10236. [PubMed] [Google Scholar]
  11. Lazrek Y, Dubreuil O, Garambois V, et al. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP and FoxO1 phosphorylation. Neoplasia 2013 ; 15 : 335–347. [CrossRef] [PubMed] [Google Scholar]
  12. Gaborit N, Abdul-Hai A, Mancini M, et al. Examination of HER3 targeting in cancer using monoclonal antibodies. Proc Natl Acad Sci USA 2015 ; 112 : 839–844. [CrossRef] [Google Scholar]
  13. Gaborit N, Larbouret C, Vallaghe J, et al. Time resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies. J Biol Chem 2011 ; 283 : 11337–11345. [CrossRef] [Google Scholar]
  14. Thomas G, Chardès T, Gaborit N, et al. HER3 expression as a predictive biomarker of the efficacy of pertuzumab in pancreatic cancer. Oncotarget 2014 ; 5 : 7138–7148. [PubMed] [Google Scholar]
  15. Larbouret C, Robert B, Navarro-Teulon I, et al. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res 2007 ; 13 : 3356–3362. [CrossRef] [PubMed] [Google Scholar]
  16. Larbouret C, Gaborit N, Chardès T, et al. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors down-regulation and dimers disruption. Neoplasia 2012 ; 14 : 121–130. [CrossRef] [PubMed] [Google Scholar]
  17. Larbouret C, Robert B, Bascoul-Mollevi C, et al. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol 2010 ; 21 : 98–103. [CrossRef] [PubMed] [Google Scholar]
  18. Assenat E, Azria D, Mollevi C, et al. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the therapy phase 1-2 trial. Oncotarget 2015 ; 5 (sous presse). [Google Scholar]
  19. Bodmer A, Goetsch L, Favet L, et al. Anticorps et tumeurs solides : cibles établies et pistes prometteuses. Med Sci (Paris) 2009 ; 25 : 1090–1098. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  20. Montagne R, Furla A, Kherrouche Z, Tulasne D. Le récepteur Met fête ses 30 ans. Med Sci (Paris) 2014 ; 30 : 864–873. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.